RecruitingPhase 3NCT06936774

Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance

Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance - a Randomized Controlled Trial (iRECOVER)


Sponsor

University Hospital, Basel, Switzerland

Enrollment

140 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical study is to gain further insights into the treatment of patients with Low Anterior Resection Syndrome (LARS) symptoms after rectal resection. The main question is: Can LARS symptoms and quality of life be improved by implementing an intensified follow-up program? Researchers will compare the results of the intervention group with the results of a control group in which patients do not receive an intensified follow-up program to determine whether the intervention works. Participants will undergo an intensified follow-up program which consists of several follow-up visits and medical treatment, pelvic floor muscle training and gynaecological and urological co-treatment in case of LARS symptoms and urinary or sexual complaints.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • patients older than 18 years
  • patients with rectal cancer in the middle and lower third of the rectum in stages I to IV who underwent LAR with TME and protective ileostomy
  • able to give informed consent as documented by signature

Exclusion Criteria2

  • dementia or other psychiatric disorder that would prevent the patients from answering the questionnaires and experiencing sustainable training effects
  • impossibility of stoma reversal due to persistent anastomotic leak and/or local recurrence

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERIntensified follow-up program

The study intervention will be an intensified follow-up program which consists of different measures. Patients will attend follow-up visits 1, 4, 7 and 13 months after ileostomy repositioning, at which LARS symptoms, quality of life as well as sexual and urinary function will be recorded using various questionnaires. In case of LARS symptoms patients will receive medical treatment with loperamide and metamucil as well as pelvic floor muscle training (including biofeedback and home exercises). Regarding pelvic floor muscle training we are planning nine sessions instructed by physiotherapy staff. In case of therapy-resistant LARS symptoms after 6 months sacral neurostimulation is offered to the patients with a focus on incontinence symptoms and desire for surgery or transanal irrigation in patients with a focus on voiding disorders. In case of urinary and sexual complaints patients are referred to our urology or gynaecology department for further diagnostic and treatment.


Locations(5)

Clarunis Universitäres Bauchzentrum Basel

Basel, Switzerland

Lindenhofspital Bern

Bern, Switzerland

St. Anna Spital Bern

Bern, Switzerland

Kantonsspital Luzern

Lucerne, Switzerland

Kantonsspital Winterthur

Winterthur, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06936774


Related Trials